NCT00596804 2021-08-18
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 1/2 Completed
Gilead Sciences
Gilead Sciences
Weill Medical College of Cornell University
Ohio State University Comprehensive Cancer Center